JP2023539390A - ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用 - Google Patents

ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用 Download PDF

Info

Publication number
JP2023539390A
JP2023539390A JP2023537445A JP2023537445A JP2023539390A JP 2023539390 A JP2023539390 A JP 2023539390A JP 2023537445 A JP2023537445 A JP 2023537445A JP 2023537445 A JP2023537445 A JP 2023537445A JP 2023539390 A JP2023539390 A JP 2023539390A
Authority
JP
Japan
Prior art keywords
alkyl
group
hydrogen atom
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537445A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022047583A5 (https=
JP2023539390A5 (https=
Inventor
エム． ハーゲル，ジリアン
ジェイ． ファッキーニ，ピーター
リン，チャン－チュン
Original Assignee
エンベリック バイオサイエンシズ カナダ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンベリック バイオサイエンシズ カナダ インコーポレイテッド filed Critical エンベリック バイオサイエンシズ カナダ インコーポレイテッド
Publication of JP2023539390A publication Critical patent/JP2023539390A/ja
Publication of JPWO2022047583A5 publication Critical patent/JPWO2022047583A5/ja
Publication of JP2023539390A5 publication Critical patent/JP2023539390A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01005—Arylamine N-acetyltransferase (2.3.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/0102—Tryptophan synthase (4.2.1.20)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023537445A 2020-09-02 2021-09-02 ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用 Pending JP2023539390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073534P 2020-09-02 2020-09-02
US63/073,534 2020-09-02
PCT/CA2021/051214 WO2022047583A1 (en) 2020-09-02 2021-09-02 Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder

Publications (3)

Publication Number Publication Date
JP2023539390A true JP2023539390A (ja) 2023-09-13
JPWO2022047583A5 JPWO2022047583A5 (https=) 2024-09-04
JP2023539390A5 JP2023539390A5 (https=) 2024-09-04

Family

ID=80492288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537445A Pending JP2023539390A (ja) 2020-09-02 2021-09-02 ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用

Country Status (10)

Country Link
US (1) US20230040398A1 (https=)
EP (1) EP4208446A4 (https=)
JP (1) JP2023539390A (https=)
KR (1) KR20230061473A (https=)
CN (1) CN116782896A (https=)
AU (1) AU2021336667A1 (https=)
CA (1) CA3191095A1 (https=)
IL (1) IL301028A (https=)
MX (1) MX2023002619A (https=)
WO (1) WO2022047583A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
EP4291549A4 (en) 2021-02-12 2025-01-22 Enveric Biosciences Canada Inc. MULTISUBSTITUENT PSILOCYLYBINDER DERIVATIVES AND METHODS OF USE
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493544A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
KR20250097973A (ko) * 2022-11-18 2025-06-30 인베릭 바이오사이언시스 캐나다 인크. 치환된 n-프로필아민 융합 헤테로사이클릭 메스칼린 유도체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532209A (ja) * 2001-03-29 2004-10-21 イーライ・リリー・アンド・カンパニー ５−ｈｔ６受容体の拮抗薬としてのｎ−（２−アリールエチル）ベンジルアミン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083918A1 (en) * 1998-06-08 2001-03-21 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
KR20030046395A (ko) * 2000-07-28 2003-06-12 인스파이어 파마슈티컬스 인코퍼레이티드 인돌 유도체를 사용하여 안압을 감소시키는 방법
EP1747779A1 (en) * 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
CN103601662B (zh) * 2013-11-21 2016-04-06 深圳市药品检验所 一种褪黑素半抗原、褪黑素完全抗原及其制备方法和应用
WO2015140799A1 (en) * 2014-03-18 2015-09-24 Carmel-Haifa University Economic Corp. Ltd Methods for improving cognitive function via modulation of quinone reductase 2
EP3532492A4 (en) * 2016-10-26 2020-10-14 University of Florida Research Foundation, Incorporated HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYZERS
WO2018106907A1 (en) * 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US10640508B2 (en) * 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532209A (ja) * 2001-03-29 2004-10-21 イーライ・リリー・アンド・カンパニー ５−ｈｔ６受容体の拮抗薬としてのｎ−（２−アリールエチル）ベンジルアミン

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM., vol. 15, JPN6025024110, 2007, pages 4543 - 4551, ISSN: 0005749202 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, JPN6025024112, 2015, pages 3597 - 3600, ISSN: 0005749204 *
PAKISTAN J. SCI. IND. RES., vol. 26, no. 2, JPN6025024111, 1983, pages 53 - 58, ISSN: 0005749203 *
REGISTRY(STN)[ONLINE], JPN7025002614, ISSN: 0005749205 *

Also Published As

Publication number Publication date
AU2021336667A1 (en) 2023-03-30
EP4208446A4 (en) 2024-10-30
US20230040398A1 (en) 2023-02-09
CA3191095A1 (en) 2022-03-10
IL301028A (en) 2023-05-01
AU2021336667A8 (en) 2023-04-13
KR20230061473A (ko) 2023-05-08
EP4208446A1 (en) 2023-07-12
WO2022047583A1 (en) 2022-03-10
MX2023002619A (es) 2023-04-10
CN116782896A (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
JP2023539390A (ja) ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用
US12187679B2 (en) Hydroxylated psilocybin derivatives and methods of using
US12138276B2 (en) Halogenated psilocybin derivatives and methods of using
US11931338B2 (en) Nitrilated psilocybin derivatives and methods of using
JP2024506667A (ja) 多置換シロシビン誘導体およびその使用方法
US20230044216A1 (en) Aldehyde and ketone derivatives of psilocybin and methods of using
CN111727191A (zh) 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途
US20260103442A1 (en) Aminated psilocybin derivatives and methods of using
EP2994122A1 (en) Novel transcription factor modulators
EP3506983B1 (en) Substituted urea-derivatives for the treatment of pain
CN118239946A (zh) 作为癌症高表达蛋白（hec1蛋白）降解剂的化合物
US12195439B1 (en) C1-substituted isopropylamine fused heterocyclic mescaline derivatives
WO2024178504A1 (en) Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using
US12358885B2 (en) Substituted n-propylamine fused heterocyclic mescaline derivatives
US20240246924A1 (en) Substituted ethylamine fused heterocyclic mescaline derivatives
WO2023102659A1 (en) Glycosylated isopropylamine mescaline derivatives and methods of using
CN103910718B (zh) 双环取代的吡唑酮偶氮类化合物、其制备方法和用途
CN115677703A (zh) 吡啶酮类化合物及其用途
WO2018119432A1 (en) Angiogenin-boronic acid conjugates with selective neuroprotection activity
WO2016201662A1 (en) Fluoropyridyl pyrazol compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209